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Abstract
This study explored expression of the START domain family in hyperinsulinaemic, genetically obese rodents, 
and the functional roles of cytosolic StarD4 and StarD5 proteins in hepatic lipid synthesis and export. Genetic 
obesity in (fa/fa) Zucker rats repressed StarD4, StarD5, StarD8 and StarD13, and decreased levels of cytosolic 
StarD4 and StarD5 proteins, compared with lean controls, suggesting links with hepatic storage or secretion of lipids. 
Stable overexpression of STARD4 in rat McArdle RH7777 hepatoma cells increased lipidation of exogenous ApoA-I 
compared with empty vector (EV) control, modestly increased secretion of endogenously synthesized cholesterol 
and reduced incorporation of [14C]oleate into cellular cholesteryl esters. Synthesis and secretion of triacylglycerol 
did not change in STARD4 overexpressing cells. By contrast, STARD5 overexpression did not alter cholesterol 
synthesis, secretion, or lipidation of apoA-I, but increased synthesis of triacylglycerol from [3H]glycerol under basal 
conditions, enhanced incorporation of [14C]oleate into triacylglycerol, and increased expression of Dgat1 and Dgat2 
compared with EV.
In summary, cytosolic STARD4 impacts predominantly on cholesterol efflux to apoA-I, implying directional 
transport of cholesterol to the plasma membrane, while STARD5 increases basal triacylglycerol synthesis and 
enriches this pool with exogenous fatty acids. Cytosolic StarD proteins may be involved in diabetic dyslipidaemia 
and steatosis.
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Introduction
Non-vesicular trafficking of lipids is mediated by two major gene 
families: the oxysterol-binding protein (OSBP) related proteins (ORPs) 
[1,2] and the steroidogenic acute regulatory protein (StAR)-related 
lipid transfer (START) domain family [3-5]. The START domain is a 
~210 amino acid α/β helix-grip fold, found in 15 distinct mammalian 
proteins (STARD1-D15), providing an adaptable hydrophobic lipid 
binding or sensing site for cholesterol, oxysterols, phospholipids, 
ceramides and small drug molecules. Phylogenetic analysis divides the 
family into six subfamilies, based on sequence and ligand similarities, 
and, more recently, comparative structural analysis [3-6]. In brief, 
the STARD1 (STARD1/D3) and STARD4 (D4/D5/D6) groups bind 
cholesterol and oxysterols, while the STARD2 (STARD2/D7/D10/
D11) group exhibits specificity for phospholipids and ceramides. Other 
members of the family include multi-domain proteins, linking the 
START domain with Rho GTPase (STARD8/D12/D13) or thioesterase 
(StARD14/D15) activities; the last member of the family is STARD9 
[3-6].
Loss of function mutations in humans and genetic deletion studies 
in mice have revealed a range of phenotypes resulting from loss of 
differing members of the START domain family. Mutations affecting 
the function of the mitochondrial cholesterol trafficking protein, 
STARD1, cause congenital lipoid hyperplasia [7], while genetic deletion 
of StarD11 (CERT) which transports ceramides from the ER to the 
Golgi, is embryonic lethal in mice, due to mitochondrial disruption 
[8]. Targeted deletion of the RhoGAP START, Stard12, thought to be 
involved in regulating the formation of focal adhesion, also results in 
embryonic lethality, presumably due to loss of cytoskeletal organisation 
[9]. 
By contrast, deletion of the START domain from endosomal 
cholesterol transporter StarD3 results in modest changes in lipid 
metabolism [10]. Deletion of StarD4 leads to modest weight reduction, 
and decreased bile cholesterol and phospholipid concentrations in 
female mice; when challenged with a 0.5% cholesterol diet, female 
StarD4 (-/-) mice also evidenced moderate decreases in total cholesterol, 
LDL and cholesteryl ester concentrations [11]. Stard2/PCTP knockout 
mice exhibit a normal phenotype, but recent data suggest StarD2 as an 
important determinant of hepatic insulin sensitivity [12]. Finally, loss 
of Stard13, results in healthy, fertile mice, indicating that this protein 
cannot compensate for the loss of Stard12 (above) [13].
These studies have highlighted the differing roles of START family 
members in lipid sensing, trafficking and signalling, but relatively 
few studies have identified differences in expression of this family 
of proteins in disease states, such as obesity or diabetes, which are 
closely associated with cardiovascular disease. This study examined 
the expression of StarD lipid trafficking proteins in the Zucker (fa/
fa) rodent model of leptin receptor deficiency [14], and explored the 
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functional role of cytosolic StarD4 and StarD5 proteins in hepatic 
synthesis and export of lipids by genetically manipulating expression 
of these proteins in rat McArdle RH7777 hepatoma cells. 
Methods
Heterozygous Zucker rats (Fa/fa) were purchased from Harlan 
Laboratories, and sodium pentobarbital from J.M. Loveridge plc 
(Southampton). Tissue culture reagents were supplied by Lonza, and 
sterile tissue culture plastics from Greiner; STARD4 and STARD5 
clones (pCMV) were purchased from Origene.com via Cambridge 
Biosciences. Apolipoprotein A-I was from Athens Research and 
Technology (Georgia, USA) and radiochemicals purchased from Perkin 
Elmer. Tri-Fast was from PeqLab, cDNA synthesis kits from Bioline, 
primers and probes (FAM/TAMRA) from EuroGenTech. Rabbit 
polyclonal antibodies to Gapdh, StarD4 and StarD5 were purchased 
from AbCAM, Santa Cruz and Biorbyt, respectively. Complete™ 
protease inhibitor cocktail was purchased from Roche. Chemicals, 
t.l.c.plates and solvents were purchased from Sigma Aldrich. 
Experimental animals
Heterozygous Zucker rats (Fa/fa) were maintained in group (n=3) 
cages on sawdust bedding, on a 14h-light/10h-dark cycle with standard 
chow and water provided ad libitum. Male lean (Fa/?; n=10) and obese 
(fa/fa; n=6), and female lean (n=5) and obese (n=4) rats were terminally 
anaesthetized at four months, using pentobarbital sodium (100 mg kg-1, 
I.P) [14]. Principles of laboratory animal care (NIHA publication no. 
85-23, revised 1985 (http://grants1.nih.gov/grants/olaw/references/
phspol.htm) were followed. The study was approved by the institution’s 
Animal Ethics and Welfare Committee, and procedures performed 
according to the UK Animals (Scientific Procedures) Act, 1986.
Preparation of tissue samples
Samples (100 mg) of liver were suspended in Dulbecco’s phosphate 
buffered saline (1 ml), using a Beadbeater (Thistle Scientific, UK), and 
a Bligh and Dyer (1959) lipid extraction performed [15]. Lipid extracts 
were dried under N2, and lipid mass measured, as described [16-18]. 
Total RNA from liver (60 mg) was isolated after homogenisation in 500 
μl of TriFast™, genomic DNA removed by treatment with DNase, and 
cDNA prepared by reverse transcription; negative controls, omitting 
reverse transcriptase enzyme, were included for each sample. Hepatic 
protein lysates were prepared in RIPA buffer plus Complete™ protease 
inhibitor cocktail. 
Cell culture and experiments
Rat McArdle RH7777 (CRL-1601; ATCC) cells, derived from 
female Rattus norvegicus (Morris hepatoma 7777) were maintained 
in DMEM (Dulbecco’s Modified Eagle Medium) containing foetal 
bovine serum (10% v/v), penicillin/streptomycin (50 U/ml, 50 μg/ml 
respectively), sodium bicarbonate (NaCO3 0.06% w/v), HEPES buffer 
(10 mM) and L-glutamine (2 mM), at 37°C in a humidified atmosphere 
of 95% air and 5% CO2. Transfection of McArdle cells with 2 μg of 
empty vector (EV; pCMV.Neo) or this vector encoding full length 
human STARD4 or STARD5 was achieved using Amaxa Nucleofector-
II (Kit V, protocol T-028). Stable populations were selected using 
G418 (1.6 mg ml-1) and then maintained at 400 μg ml-1. Differences in 
nutrient partitioning between McArdle hepatoma cells and primary rat 
hepatocytes are described in [19]. 
Lipidation of apoA-I (10μg ml-1; 24h) was assessed in cells labelled 
with 0.5 μCi ml-1 [3H]cholesterol, as described [16-18,20]. For lipid 
synthesis and secretion experiments, cells were cultured in serum-free 
DMEM in presence of [1-2 14C] acetate (1.5 µCi/ml; 0.5 mM), [1-14C]
oleate (1 µCi/ml; 0.7 mM complexed 1:1 with BSA) or [2-3H] glycerol 
(1.18 µCi/ml; 0.25 mM) for 2h, in the presence or absence of 0.35mM 
oleate/BSA (1:1) complex; concentrations of acetate (0.5 mM) and 
glycerol (0.25 mM) remained the same under all conditions tested. 
Note that the data for the EV control was previously reported in [20].
Lipid analyses
Samples of media were extracted according to Bligh and Dyer 
(1959), and cellular lipids using hexane:isopropanol (3:2, v/v), as 
detailed [16-18,20], and extracts dried under N2 before resuspension 
in isopropanol containing rat liver lipids, and separation by t.l.c. using 
petroleum ether: diethyl ether: glacial acetic acid (90:30:1 by vol.) as 
the mobile phase. Lipids were identified by comparison with authentic 
standards, and dpm determined by scintillation counting (Hidex 
300SL); lipid mass was measured using colorimetric assays as described 
previously [16-18,20].
Gene and protein analyses
Total RNA from liver (60 mg) was isolated after homogenisation 
in 500 μl of TriFast™ (PeqLab, UK); genomic DNA removed by 
treatment with DNase (Ambion®, UK), and cDNA prepared by reverse 
transcription (Bioline, UK); negative controls, omitting reverse 
transcriptase enzyme, were included for each sample. Levels of mRNA 
encoding StarD proteins were measured relative to Gapdh, as described 
[16-18,20]; specific sequences for primers and fluorescent probes 
(FAM/TAMRA) are reported in Table 1. Gene and/or protein levels of 
StarD1 and StarD3 were reported [20].
Gene expression of Dgat1 and Dgat2, relative to Gapdh, were 
measured using commercial primers and Sybr Green (Maxima 
SYBR Green QPCR Master Mix), using the following primer 
sequences: Dgat1 sense (5’-CGGATAGCTTACAGTGTTCTG-3’), 
antisense (5’-CATCATACTCCATCATCTTCCTCA-3’); Dgat2 
sense (5’-GCCAGGTGACAGAGAAGATG-3’), antisense 
(5’-GCAGCGAGAACAAGAATAAAG-3’) and Gapdh, 
sense (5’-GTAACCAGGCGTCCGATAC-3’) and antisense 
(5’-TCTCTGCTCCTCCCTGTTC-3’). Results are expressed as ratio to 
Gapdh, using the 2-∆Ct comparison method (Applied Biosystems) 
Hepatic protein lysates were separated using 10% (w/v) SDS PAGE 
gels, transferred to nitrocellulose membranes, and probed using rabbit 
polyclonal antibodies to StarD4 (1:1000), StarD5 (1:1000) and Gapdh 
(1:1000) as previously [16-18,20], except that fluorescently-labelled 
secondary antibodies (Licor) were employed and bands quantified 
using a Licor Odyssey FC and Image Studio software. 
Statistical analysis
All values indicate mean ± SEM; n denotes numbers of independent 
determinations. Significant (p<0.05) differences were determined by 
Student’s t-test.
Results
Hepatic expression of genes encoding the StarD family in fa/
fa and Fa/? rats
Gene expression of the StarD lipid trafficking proteins in liver 
samples from male and female, obese Zucker (fa/fa) and lean (Fa/?) 
rats (4 months old) are shown in Figure 1. Bioinformatic analyses of 
the -3kb promoter region of each family member revealed a number of 
putative response elements for lipid responsive transcription factors, 
including sterol element binding proteins and peroxisome proliferator 
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activated receptors [data not shown]. Gene expression of 12 of the 15 
mammalian START proteins were detected in rodent liver. Repression 
of StarD5 (p<0.01), StarD8 (p<0.01) and StarD13 (p<0.05) were noted 
in obese male, compared with lean male rodents. Obesity in female rats 
was associated with decreased hepatic expression of Stard4 (p<0.01) 
compared with lean female controls. The level of StarD6 mRNA 
was extremely low in hepatic tissues from male and female rodents. 
No significant changes in expression were noted for genes encoding 
phospholipid and ceramide transporters (StarD2 subgroup), StarD9, 
RhoGAP StarD12, or the thioesterase, StarD15.
Hepatic expression of StarD4 and StarD5 proteins in fa/fa 
and Fa/? rats












































































Figure 1: Gene expression, relative to Gapdh, of StarD2, StarD4, RhoGAP and Thioesterase START  family subgroups, and StarD9, in lean (plain bars) and obese 
(hatched bars), male (light grey bars) and female (dark grey bars) Zucker rats; values are mean ± SEM from four animals in each group.
Gene Forward primer sequence (5’-3’)




StarD2 GGACCCCCGCATCCAT CGCTTTGAAGGTGGGAACA TGCTACACCAACTGAAGCTCGCCCTT
StarD4 CAGAGTCTCCTGACAGGCTACATC TGCTTGCCATTGCTGTGTCT ACAGACCTGCGTGGCATGATCCC
StarD5 GCATCACGGATACGCTGTGT CTGGGCGAATCAGCTTCAT CAGAACCTCCACGCCCTCAGCTG
StarD6 AAAAGAAGGTGCCATCTCAACAA CAGATGAAGCCAAGGGTGTCT TCTGGCTTCCACTGACCCAATGGC
StarD7 TGGAATGAGCAGTGAGGCTAA GCCACAGCTACCCTCATTCTTC CCACTGCTTCGTCCCCCGAGC
StarD8 CCTCACAAGCGAAGAGAATCTTG GGCCTCCAGATGCAGTAGCA AAGAAGATCGTTGCTGTCCACCTGACCA
StarD9 TTCAGTACCAGCCCCGTTGT CGCAAGAAAACCAGGAATCC CCGAACAAATCAACCCTCTCCGAGGTA
StarD10 TCCCCACGCTCTCTATGGAA GACACCTTCACGGCCCAAAG AGCCAGCTGCTTCAACAGAACCCCA
StarD11 AGACGAGTAGAGGAAGCATACAAGAAT TCAAGAACTCTTCCTCATTAATCAGACT AACCTCGCTTCGGAGGGCCAGACTAT
StarD12 GGGCAAACCAGACCAGAAG TGCACTCGGCAATCATGTG TCTGAATGAAAACCTAGCCGCCACTCA
StarD13 CAAGAAATCGAGGCGAAGGA TGTTGATGGGAAACTGCGAAT CTGCGAGCTGCCGGGTTCCC
StarD14 GCGCCGGCACATCAA CTTCTGAGGCTGGTCATCTTTGT AGCGCCTTCATGACTTTCGTGGTCC
StarD15 CGCCGGGCAACTACTTAAGT CAGGAATCCCAGCATGCTT ACTGCCTGCCTGGCCGCTGA
Gapdh CAACTACATGGTCTAGTTCCAGTATG CTTCCCATTCTCAGCCTTGACGT CTACCCACGGCAAGTTCAACGGCA
Table 1: Primer and probe sequences used to investigate gene expression of StarD proteins in samples of rodent liver.
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to Gapdh, exhibited marked regulation compared with their gene 
expression (Figure 2). Obesity was associated with repression of hepatic 
StarD4 expression in both male (15.6-fold; p<0.01) and female (6.55-
fold; p<0.01) rats. By contrast, hepatic levels of StarD5 protein were 
significantly repressed (3.2-fold; p<0.001) by obesity in female, but not 
male rats, compared with lean controls. 
Cholesterol metabolism in hepatoma cells overexpressing 
STARD4 and STARD5
Human cytosolic STARD4 and STARD5 proteins, and an empty 
vector (EV) control, were stably overexpressed in rat McArdle (McA-
RH7777) hepatoma cells (Figure 3A); note that the data for the EV 
control was previously reported in [20]. Alignment of rodent and 
human amino acid sequences (ClustalW) revealed 84% and 88.78% 
identity, for StarD4/STARD4 and StarD5/STARD5, respectively. The 
efflux of [3H]cholesterol to exogenous human ApoA-I (10 μg ml-1; 24h) 
from STARD4 and STARD5 overexpressing cells are shown in Figure 
3B. Overexpression of STARD4 significantly increased lipidation 
of ApoA-I by nearly two-fold, compared with EV and STARD5 
overexpressing cells. The effects of overexpression of STARD4 and 
STARD5 on synthesis and secretion of de novo synthesized cholesterol 
and cholesteryl esters derived from [14C]acetate (0.5mM; 2h) are 
shown in Figures 4A to 4D, and on the incorporation of [14C]oleate 
(0.7mM; 2h) into cellular and secreted cholesteryl esters, are shown 
in Figures 4E and 4F. The effect of STARD4 and STARD5, compared 
with the EV control, were compared under basal conditions, and after 
challenge with 0.35mM oleate to stimulate neutral lipid synthesis and 
secretion. A modest increase in secretion of [14C]cholesterol was noted 
under basal conditions (31%; p<0.05) in STARD4 overexpressing cells. 
Measurement of incorporation of exogenous oleate into the cholesteryl 
ester pool (Figure 4E) revealed a significant decrease in STARD4 
overexpressing cells, compared with STARD5 overexpressing cells; in 
the presence of 0.35mM cold oleate, this decline was also significant 
when compared with the EV control. No changes in secretion of 
cholesteryl [14C]oleate were evident (Figure 4F). Analysis of the 
total cholesterol mass of EV (0.49 ± 0.06 mg mg-1 protein), STARD4 
(0.46±0.16 mg mg-1 protein) and STARD5 (0.44 ± 0.19 mg mg-1 protein) 
hepatocytes revealed no significant changes, either in the absence or 
presence of 0.35 mM oleate.
Triacylglycerol synthesis in hepatoma cells overexpressing 
STARD4 and STARD5
The synthesis and secretion of triacylglycerol from [3H]glycerol 
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Figure 2: Expression of cytosolic StarD4 (2A) and StarD5 (2B) proteins, relative to Gapdh, in hepatic tissues from lean and obese, male and female Zucker rats; 
values are the mean±SEM from 4 animals in each group.
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Figure 3: Expression of STARD4 and STARD5 in McArdle RH7777 hepatoma cells, stably transfected with empty vector (EV; pCMV.Neo), or the same vector 
encoding each gene of interest (full length STARD4 or STARD5) are shown in Figure 3A.  Lipidation of apoA-I (10μg ml-1; 24h) with [3H]cholesterol by these 
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Figure 4: Incorporations (2h) of 0.5mM [14C]acetate into cellular (4A) and secreted (4B) cholesterol, cellular (4C) and secreted (4D) cholesteryl esters, and of 
0.7mM [14C]oleate into cellular (4E) and secreted (4F) cholesteryl ester pools, in the presence or absence of 0.35mM cold oleate, in EV, STARD4 and STARD5 
overexpressing hepatoma cells.  Values are mean ± SEM for three independent experiments.
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(0.25 mM; 2h), [14C]acetate (0.5 mM; 2h) and [14C]oleate (0.7mM; 
2h) are shown in Figure 5. Again, the effect of STARD4 and STARD5, 
compared with EV control, were compared under basal conditions, and 
after challenge with 0.35mM oleate to stimulate neutral lipid synthesis 
and secretion. When total triacylglycerol synthesis and secretion 
was monitored using [3H]glycerol (0.25mM; 2h), the stimulatory 
effect of STARD5 overexpression on triacylglycerol synthesis was 
evident, at least under basal conditions (Figure 5A). No changes in 
secretion of triacyl[3H]glycerol were observed compared with the 
EV control (Figure 5B). No changes in the synthesis or secretion of 
triacylglycerol derived from endogenous lipogenesis were noted in 
cells overexpressing STARD4 or STARD5, compared with EV (Figures 
5C and 5D, respectively). By contrast, overexpression of STARD5 
stimulated the incorporation of exogenous [14C]oleate into the cellular 
(Figure 5E), but not secreted (Figure 5F), triacylglycerol pool, mirroring 
the findings in Figure 5A. The triacylglycerol mass tended to increase in 
the presence of 0.35mM oleate (2h) in EV (0.89 ± 0.06 mg mg-1 protein 
versus 0.35mM oleate 1.07 ± 0.15 mg mg-1 protein; n=3; non-significant 
(NS)), STARD4 (0.72 ± 0.26 mg mg-1 protein versus 1.01 ± 0.23 mg mg-1 
protein; n=3; NS) and STARD5 overexpressing cells (0.75 ± 0.29 mg 
mg-1 protein versus 1.32 ±0.47 mg mg-1 protein; n=3; NS). 
The expression levels of Dgat1 and Dgat2 in EV, STARD4 and 
STARD5 overexpressing hepatoma cell lines are shown in Figure 
6. Overexpression of STARD4 increased expression of Dgat1, but 
decreased the levels of Dgat2 mRNA levels, compared with the EV 
control. By contrast, overexpression of STARD5 enhanced expression 
of both Dgat1 and Dgat2. 
Discussion
Obesity alters gene expression of StarD4 and Rho-GAP subgroups 
of the START family of lipid trafficking proteins, which may impact 
on the efficiency of hepatic lipid transport, a key issue in diabetic 
dyslipidaemia and non-alcoholic fatty liver disease (Figure 1). At four 
months, fa/fa rats are normoglycaemic and hyperinsulinaemic [14], 
hyperlipidaemic and steatotic, compared with lean controls [20]; 
moreover, obese male Zucker rats exhibit greater accumulation of 
hepatic triacylglycerol and phospholipid mass than obese female rats, 
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Figure 5: Incorporations (2h) of 0.25mM [3H]glycerol, 0.5mM [14C]acetate and 0.7mM [14C]oleate into cellular (5A, 5C, 5E) and secreted (5B, 5D, 5F) triacylglycerol, 
in the presence and absence of 0.35mM cold oleate, in EV, STARD4 and STARD5 overexpressing hepatoma cells. Values are mean ± SEM for three independent 
experiments.
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while a more profound hyperlipidaemia is evident in female rats [20,21]. 
Interpreting the outcome of individual changes in gene expression is 
complex, as the relationship between StarD mRNA and protein levels 
is not necessarily linear, presumably mediated via post-translational 
mechanisms (Figure 2). However, it is tempting to speculate that 
repression of genes encoding tumour suppressor proteins, StarD8 and 
StarD13, could contribute to the incidence of hepatocellular carcinoma 
associated with obesity [22]. 
Clearly, however, hepatic expression of StarD4 protein, relative to 
Gapdh, is repressed by obesity in male and female rats. Levels of StarD4 
mRNA and protein have previously been shown to be repressed by 
cholesterol accumulation in fibroblasts and liver tissues [23,24], while 
female mice are more affected by global genetic deletion of StarD4 than 
male animals [11]. By contrast, StarD5 is expressed at much lower 
levels than StarD4 in liver tissues, when expressed as a ratio to Gapdh, 
and is repressed by obesity only in female rats. Previous work has 
suggested that StarD5 is found within the sinusoidal lining cells in the 
human liver, co-localized with CD68, a marker for Kupffer cells [25]; 
however, StarD5 protein was clearly present in McArdle hepatoma 
cells (Figure 3). Unlike StarD4, which is regulated by sterol regulatory 
element binding protein -2 (SREBP-2) and is therefore repressed in 
tissues accumulating cholesterol [23,24], the promoter region of StarD5 
does not contain a SRE [24]. Instead, StarD5 expression increases in 
macrophages loaded with free cholesterol [24], as a consequence of 
activation of the endoplasmic reticulum stress response. These findings 
led to the suggestion that StarD4 and StarD5 might serve differing roles 
in lipid metabolism [24]. 
Indeed, given the hepatic and serum lipid profile of fa/fa rats 
[20], we initially speculated that StarD4 might facilitate lipid export 
from the liver, while StarD5 could be linked with hepatic lipid 
accumulation. Certainly, overexpression of STARD4 increased the 
lipidation of exogenous apoA-I, one measure of hepatic ABCA1 
activity [21] suggesting an association with serum or HDL lipid levels 
(Figure 3B). A small increase in secretion of endogenously synthesized 
cholesterol was also noted in the absence of apoA-I, which may 
reflect efflux to endogenously produced apoA-I. However, despite the 
reciprocal relationship that exists between hepatic ABCA1 activity 
and output of VLDL [26-28], and evident changes in Dgat1/Dgat2 
ratio (Figure 6), no changes in synthesis or secretion of triacylglycerol, 
from either endogenous or exogenous fatty acids, were observed in 
STARD4 overexpressing cells. Instead, reduced incorporation of 
exogenous [14C]oleate into the cholesteryl ester pool was evident in 
STARD4 overexpressing hepatoma cells, compared with STARD5 
overexpressing cells or EV controls (Figure 4E). This was particularly 
surprising, given previous findings indicating that StarD4/STARD4 
activity is associated with increased delivery of sterol to the endocytic 
recycling compartment (ERC) and the endoplasmic reticulum and 
enhances ACAT-dependent deposition of cholesterol ester mass in 
macrophages, fibroblasts, hepatocytes and hepatoma cells [29-32]. 
The most obvious difference in our study, compared with these 
reports [29-32], is the challenge posed by exposure to a physiologically 
relevant (0.7mM) concentration (of (radiolabelled) oleate in the 
culture medium. It is possible that STARD4 can act as a bi-directional 
cholesterol transporter, capable of shuttling cholesterol to and from the 
endoplasmic reticulum, depending upon the cellular milieu. Certainly, 
overexpression of STARD4 facilitated removal of cholesterol from the 
plasma membrane (Figure 3B). In good agreement with the former, 
knockdown of STARD4 led to retention of cholesterol at the plasma 
membrane in HepG2 cells [32]. STARD4 can also facilitate bile acid 
formation [29], so that cholesterol may be preferentially directed 
towards metabolism rather than storage: the McArdle RH7777 cell 
line used in this study expresses both cholesterol 7α-hydroxylase and 
CYP27A1 [20]. 
Neutral lipid metabolism was differentially regulated by STARD5, 
compared with STARD4, in McArdle hepatoma cells. No observable 
effects on cholesterol efflux, endogenous cholesterol and cholesteryl 
ester biosynthesis, and incorporation of exogenous oleate into the 
cholesteryl ester pool were evident. Indeed, controversy exists as to 
whether StarD5 actually binds sterols [33-36]. Rodriguez-Agudo et al. 
[33] reported that StarD5 bound cholesterol and 25-hydroxycholesterol, 
and that overexpression of this protein in hepatocytes increased the 
free cholesterol content of intracellular membranes [33]. By contrast, 
Letourneau et al. [34-36] utilised nuclear magnetic resonance, circular 
dichroism and isothermal titration calorimetry to demonstrate that 
primary and secondary bile acids, and not cholesterol, were the ligands 
for StarD5, suggesting that this protein is involved in the cellular 
responses elicited by bile acids. 
In our study, overexpression of STARD5 promotes the total 
synthesis of triacylglycerol under basal conditions (Figure 5A) and the 
incorporation of exogenous [14C]oleate into this pool, in the presence 
or absence of cold oleate (Figure 5E), possibly reflecting the increased 
expression of Dgat1 (Figure 6). No changes in endogenous lipogenesis 
from [14C]acetate were noted in STARD5 overexpressing cells, 





































Figure 6: The expression of Dgat1 and Dgat2, relative to Gapdh, in EV, 
STARD4 and STARD5 overexpressing McA-RH7777 hepatoma cells; values 
are the mean ± SEM of quadruplicate determinations by Q-PCR.
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levels were also increased (Figure 6). Overexpression of STARD5 may 
therefore preferentially regulate diacylglycerol transferase-1 (DGAT-
1) activity rather than DGAT-2. DGAT-1 has dual topology, with 
cytosolic (overt) and lumenal (latent) activities which, respectively, 
allow remodelling of the triacylglycerol pool within the cytosol, and 
the generation of triacylglycerol used to lipidate nascent VLDL prior to 
secretion [37]. The activity of diacylglycerol acyl transferase-2 (DGAT-
2) is restricted to the cytosolic aspect of the endoplasmic reticulum. 
This enzyme utilises glycerol-3-phosphate and de novo synthesized 
fatty acids as substrates to form de novo synthesized triacyglycerol 
[reviewed in 37]. A minor fraction of this triacylglycerol is utilised 
for secretion with apoB, and some is stored as cytosolic lipid droplets; 
however, the majority is hydrolysed to yield partial glycerides which 
are then re-esterified by DGAT-1, which utilises exogenously derived 
fatty acids. The outcomes here suggest enhancement of overt DGAT-1 
activity in STARD5 overexpressing cells, although the mechanism(s) 
by which this is achieved remain to be established. 
Finally, our study suggests that variations in hepatic levels of 
STARD4 or STARD5 proteins may contribute to the altered lipid 
metabolism that may predispose individuals to future development of 
diabetes. It is possible that familial inheritance of altered expression 
levels of STARD4 or STARD5 may contribute to the increased risk 
of coronary heart disease observed even in non-diabetic subjects 
[reviewed in 38]. Certainly, increased circulating levels of non-esterified 
fatty acids and triglycerides can lead to ectopic lipid accumulation and 
predicate cardiac dysfunction in ‘pre-diabetic’ and diabetic individuals 
[38].
Conclusions
The cytosolic lipid trafficking proteins, STARD4 and STARD5, 
appear to exert differing effects on neutral lipid metabolism in McArdle 
RH-7777 hepatoma cells. Cytosolic STARD4 impacts predominantly 
on cholesterol efflux to apoA-I, implying directional transport of 
cholesterol to the plasma membrane, and limiting the incorporation 
of radiolabelled oleate into the hepatic cholesteryl ester pool. By 
contrast, STARD5 does not alter hepatic cholesterol metabolism, but 
increases the basal synthesis of triacylglycerol and enriches the hepatic 
triacylglycerol pool with exogenous (preformed) fatty acids, possibly 
playing a permissive role in hepatic steatosis. Thus, altered levels 
of cytosolic StarD proteins may be implicated in the pathogenesis 
associated with dyslipidaemia and/or steatosis. Further studies in 
murine models of obesity and diabetes are clearly warranted, while 
investigation of the levels of StarD proteins in diabetic patients could 
provide new insights regarding their role(s) as markers of predisposition 
to cardiovascular disease and diabetes.
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